Search

Returning search results with filters:

Issue: COVID Clear all

Type

Audience

Category

Issue

Last updated

Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.

Displaying 1 - 11 of 11 items.

" " Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines
… Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines Public advisory Seek medical … following symptoms after vaccination with the Janssen and Vaxzevria COVID-19 vaccines: unexplained bleeding, …
AlertPublic advisory | 2021-11-09
" " AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
… AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular … AstraZeneca Canada Inc. COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …
AlertHealth professional risk communication | 2021-03-24
" " AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
… AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular … AstraZeneca Canada Inc. COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …
AlertHealth professional risk communication | 2021-06-29
" " Authorization of COVISHIELD with English-only Vial and Carton Labels
… COVISHIELD (manufactured by Serum Institute of India) and AstraZeneca COVID-19 VACCINE (manufactured by AstraZeneca) are ChAdOx1-S recombinant vaccines developed by AstraZeneca and … section). Products affected COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …
AlertHealth professional risk communication | 2021-03-01
" " Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
… Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and … information during the initial distribution of the AstraZeneca COVID-19 Vaccine. Audiences Healthcare … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]), 5 mL solution for intramuscular …
AlertHealth professional risk communication | 2021-03-01
" " EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
… and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … taken by Health Canada Health Canada has worked with AstraZeneca Canada Inc. to prepare this alert for EVUSHELD. …
AlertHealth professional risk communication | 2023-01-17
" " Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
… Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and … information during the initial distribution of the AstraZeneca COVID-19 Vaccine (US-labelled vaccine supplies) … and Supplier in Canada AstraZeneca COVID-19 Vaccine, (ChAdOx1-S [recombinant]) Suspension for Intramuscular …
AlertHealth professional risk communication | 2021-03-31
" " EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
… and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … and English on Health Canada’s Drug Product Database , at astrazeneca.ca , or by scanning the QR code on the global … taken by Health Canada Health Canada has worked with AstraZeneca Canada Inc. to prepare this alert for EVUSHELD. …
AlertHealth professional risk communication | 2022-10-26
" " Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine
… Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine Starting date: March 11, 2021 … adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine, and would like to reassure … these events. To date, no adverse events related to the AstraZeneca COVID-19 vaccine, or the version manufactured by …
AlertPublic advisory | 2021-03-11
" " Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines
… Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines Starting date: … number: RA-75389 Last updated: 2021-06-29 Summary Product: AstraZeneca and COVISHIELD COVID-19 vaccines Issue: Health … is updating the product monograph—or label—for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary …
AlertPublic advisory | 2021-06-29
" " Distribution of EVUSHELD (tixagevimab and cilgavimab for injection) with English-Only Vial and Carton Labels
… EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with … recommended. In order to provide rapid access to EVUSHELD, AstraZeneca will distribute product vials and cartons with … Canadian Product Monograph (CPM), can be accessed at astrazeneca.ca , or by scanning the QR code on the global …
AlertHealth professional risk communication | 2022-04-14
Report a problem or mistake on this page
What was wrong?

If you want to receive a follow-up reply, please include your name and e-mail address.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.